FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308352561> ?p ?o ?g. }

• W4308352561 abstract "Objectives: Tumours remain a serious threat to human life. Following rapid progress in oncology research, tyrosine kinase inhibitors have been used to treat multiple tumour types. Given the great influence of kidneys on pharmacokinetics, renal toxicities associated with TKIs have attracted attention. However, the TKIs with the lowest risks of renal impairment are unclear. In this study, we conducted a Bayesian network meta-analysis to compare the incidence of renal impairment among different TKIs in patients with tumours. Methods and analysis: Six databases (PubMed, EMBASE, The Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang Data, and China Biomedical Literature Database) were electronically searched from inception to 1 November 2021 to identify randomized controlled trials on the incidence of renal impairment for different TKIs in patients with tumours. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias of the included studies. Then, a pairwise meta-analysis was conducted using Stata version 13, and network meta-analysis within the Bayesian framework was conducted using R software version 3.5.3 with the package gemtc 0.8-2 recalling JAGS (version 4.3.0). Results: Overall, 34 randomized controlled trials were included in this study. Although renal toxicity was common among patients receiving TKIs, the incidence and severity greatly differed among the drugs and studies. Elevated creatinine and protein levels were the most common nephrotoxic events, whereas haematuria was relatively rare. Among TKIs, nintedanib and ripretinib carried the lowest risks of renal impairment. Conclusion: TKIs displayed different profiles of renal toxicity because of their different targets and underlying mechanisms. Clinicians should be aware of the risks of renal impairment to select the optimal treatment and improve patient adherence to treatment. Systematic Review Registration: [www.crd.york.ac.uk/prospero/], identifier [CRD42022295853]." @default.
• W4308352561 created "2022-11-11" @default.
• W4308352561 creator A5010284290 @default.
• W4308352561 creator A5026930111 @default.
• W4308352561 creator A5029344302 @default.
• W4308352561 creator A5030602225 @default.
• W4308352561 creator A5078362508 @default.
• W4308352561 date "2022-11-03" @default.
• W4308352561 modified "2023-09-30" @default.
• W4308352561 title "Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis" @default.
• W4308352561 cites W1544142122 @default.
• W4308352561 cites W1617328014 @default.
• W4308352561 cites W1829587101 @default.
• W4308352561 cites W1938828834 @default.
• W4308352561 cites W1967792499 @default.
• W4308352561 cites W1976987666 @default.
• W4308352561 cites W1997619520 @default.
• W4308352561 cites W2010699829 @default.
• W4308352561 cites W2021988356 @default.
• W4308352561 cites W2023952988 @default.
• W4308352561 cites W2024946751 @default.
• W4308352561 cites W2047871200 @default.
• W4308352561 cites W2054774757 @default.
• W4308352561 cites W2059255702 @default.
• W4308352561 cites W2070232725 @default.
• W4308352561 cites W2071549499 @default.
• W4308352561 cites W2075535893 @default.
• W4308352561 cites W2087285553 @default.
• W4308352561 cites W2091808438 @default.
• W4308352561 cites W2100173894 @default.
• W4308352561 cites W2103667022 @default.
• W4308352561 cites W2104540972 @default.
• W4308352561 cites W2104740757 @default.
• W4308352561 cites W2110810263 @default.
• W4308352561 cites W2112099875 @default.
• W4308352561 cites W2116949558 @default.
• W4308352561 cites W2126684649 @default.
• W4308352561 cites W2126930838 @default.
• W4308352561 cites W2130224071 @default.
• W4308352561 cites W2133537644 @default.
• W4308352561 cites W2136403658 @default.
• W4308352561 cites W2139909466 @default.
• W4308352561 cites W2142656868 @default.
• W4308352561 cites W2144625636 @default.
• W4308352561 cites W2147834058 @default.
• W4308352561 cites W2148385498 @default.
• W4308352561 cites W2149654081 @default.
• W4308352561 cites W2150707594 @default.
• W4308352561 cites W2157076786 @default.
• W4308352561 cites W2161374186 @default.
• W4308352561 cites W2276228008 @default.
• W4308352561 cites W2324138891 @default.
• W4308352561 cites W2466228672 @default.
• W4308352561 cites W2501720785 @default.
• W4308352561 cites W2524769152 @default.
• W4308352561 cites W2529353359 @default.
• W4308352561 cites W2574564028 @default.
• W4308352561 cites W2589574297 @default.
• W4308352561 cites W2739010860 @default.
• W4308352561 cites W2765356289 @default.
• W4308352561 cites W2768980003 @default.
• W4308352561 cites W2772288154 @default.
• W4308352561 cites W2783640123 @default.
• W4308352561 cites W2787358630 @default.
• W4308352561 cites W2787426491 @default.
• W4308352561 cites W2789493946 @default.
• W4308352561 cites W2794124491 @default.
• W4308352561 cites W2878929600 @default.
• W4308352561 cites W2885163547 @default.
• W4308352561 cites W2895077242 @default.
• W4308352561 cites W2896175597 @default.
• W4308352561 cites W2914321117 @default.
• W4308352561 cites W2915706453 @default.
• W4308352561 cites W2923519145 @default.
• W4308352561 cites W2970684805 @default.
• W4308352561 cites W2989313910 @default.
• W4308352561 cites W2995463243 @default.
• W4308352561 cites W3030472743 @default.
• W4308352561 cites W3033611734 @default.
• W4308352561 cites W3037306288 @default.
• W4308352561 cites W3041689857 @default.
• W4308352561 cites W3092697549 @default.
• W4308352561 cites W3096583666 @default.
• W4308352561 cites W3109352373 @default.
• W4308352561 cites W3128646645 @default.
• W4308352561 cites W3130714601 @default.
• W4308352561 cites W3161525867 @default.
• W4308352561 cites W3164056006 @default.
• W4308352561 cites W3165522895 @default.
• W4308352561 cites W3165543715 @default.
• W4308352561 cites W3169953522 @default.
• W4308352561 cites W3186294428 @default.
• W4308352561 cites W3217259098 @default.
• W4308352561 cites W4249731213 @default.
• W4308352561 cites W973171548 @default.
• W4308352561 doi "https://doi.org/10.3389/fphar.2022.1023660" @default.
• W4308352561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36408227" @default.
• W4308352561 hasPublicationYear "2022" @default.
• W4308352561 type Work @default.
• W4308352561 citedByCount "0" @default.

• next